Patients of congenital diseases such as Down syndrome (DS) and Duchenne muscular dystrophy (DMD) have abnormalities in their chromosomes and/or genes. Therefore, it has been considered that drug treatments can serve to do little for these patients more than to patch over each symptom temporarily when it arises. Although we cannot normalize their chromosomes and genes with chemical drugs, we may be able to manipulate the amounts and patterns of mRNAs transcribed from patients' DNAs with small chemicals. Based on this simple idea, we have looked for chemical compounds which can be applicable for congenital diseases and found that protein kinase inhibitors such as INDY, TG003, and SRPIN340 are promising as clinical drugs for DS, DMD, and DDS, respectively.
Introduction
Congenital genetic disorders are caused by hereditary or spontaneous genetic alterations. Genetic changes may involve a single to several base mutations of a single gene, gene chimerization due to chromosomal dislocations, or amplification or deletion of multiple genes. Genetic changes may extend to larger genetic lesions of a chromosome and sometimes even its entire portion is deleted or amplified. The genetic changes may result in gain or reduction in the activity, altered function, or total loss of the genomic products, leading to the disease phenotypes. Treatments of congenital genetic disorders often pose difficult clinical challenges, because there are currently no established methods to restore the genetic changes that cause the disease. Gene therapy, the therapeutic strategy that transfers genetic materials such as DNA and RNA to affected organs, has been intensely studied (Kay, 2011) . To date, however, no gene therapy protocols have been approved by the Food and Drug Administration or European Medicines Agency, partly because of technical problems involving their delivery, immunogenicity, and adverse effects (Kay, 2011) .
The advancement of the knowledge of the molecular mechanisms that link particular genetic changes with the clinical disease symptoms began to attract the attentions of researchers on previously overlooked molecular targets. In this review, we discuss the emerging strategies to treat congenital genetic diseases with small chemical compounds and summarize our recent findings on potential drug seeds for Down syndrome (DS), Duchenne muscular dystrophy (DMD), and Denys Drash Syndrome (DDS).
"Protein-targeting" approach to treat congenital genetic defects
Some congenital genetic defects cause diseases because of the reduced activities of the affected gene products due to deletions or lossof-function mutations. In other cases, amplified copies of genomic lesions that contain pathogenic genes, or mutations that generate abnormal active forms of enzymes may cause the diseases. Chemical compounds may then counter the pathogenic process if it agonizes the reduced activities, or antagonizes the aberrant activities of the gene products. This approach is a rather conventional strategy where drug compounds target the pathogenic proteins. In case of diseases caused by gene amplification, chemical compounds may provide particularly ideal therapeutics; when a gene amplification makes an excessive activity of a pathogenic protein, carefully dosecontrolled administration of its inhibitor may restore the enzymatic activity to normal levels. Since pharmacokinetic/pharmacodynamics analysis is best studied in conventional drug treatment, chemical compound drug would be more suitable compared to other therapeutic approaches such as gene therapy (Rajman, 2008) . We recently invented an inhibitor of a DS-related kinase as a potential drug lead compound of DS as discussed later in this review.
"Ribonucleic acid-targeting" approach to treat congenital genetic defects
The emerging concept of "RNA-targeted" chemical therapy represents the idea to target the abnormal mRNA, not the protein, to ameliorate the disease symptoms. Currently investigated RNA-targeting drugs include conventional small chemical compounds and gene therapies using target sequence-specific oligonucleotides (Hagiwara, 2005; Muntoni & Wood, 2011) . In this review we will focus on the former category of the RNA-targeting drugs.
When a gene functions as a mature protein, it must be firstly transcribed and processed to a mature mRNA and then translated as a protein. The production of mature mRNAs involves multiple coordinated posttranscriptional modifications, including 5′ capping, premRNA splicing, and polyadenylation (Licatalosi & Darnell, 2010) . Other post transcriptional modifications of mRNAs include C-U and A-I RNA editing catalyzed by APOBEC1 or ADAR proteins, respectively (Mattick & Mehler, 2008) . The mature form of mRNA then undergoes a series of dynamic regulations that define the life span, translation efficiency, and the mode of their destruction, including surveillance of premature stop codons via nonsense mediated-decay, and silencing by micro RNAs (Dreyfuss et al., 2002) . Although each of these processes may represent potential targets for altering affected gene activities, this review will mainly discuss about the discovery of chemical compounds that manipulate the pre-mRNA splicing process. In some congenital genetic diseases, regulatory sequences of splicing are mutated, leading to production of aberrant forms of alternatively spliced mRNAs that impair the normal functions of affected organs. The chemical drugs may then restore the splicing patterns by targeting the enzymes that regulate the splicing machineries, such as SR protein kinases (SRPKs) and Cdc-2 like kinases (Clks) that phosphorylate and regulate the activities of splicing regulatory proteins (Muraki et al., 2004; Hagiwara, 2005; Fukuhara et al., 2006; Yomoda et al., 2008) .
Chemical treatment of Down syndrome
2.1. Down syndrome is a "gene dosage" disorder DS is the most frequent chromosomal disorder that arises once in every 733 births in the United States (Sherman et al., 2007) . DS is a congenital genetic disorder, caused by a complete or partial trisomy of human chromosome 21, and the triplicated genes exert excessive activities due to the gene dosage effects leading to formation of the disease (Antonarakis & Epstein, 2006; Wiseman et al., 2009) . Patients of DS exhibit mental retardation associated with abnormal brain development, marked by reduced number and size of neurons, reduced dendritic tree and smaller brain size (Coyle et al., 1986) . Another hallmark of DS is its associations with early-onset Alzheimer disease (AD). Studies of the brains of AD revealed that DS is strongly associated with early-onset AD. Strikingly, virtually all individuals with DS develop the typical AD histopathology of neurofibrillary tangles (NFT) and amyloid plaques when they are above the age of 30, and between 50 and 70% of DS individuals develop dementia by the age of 60 (Wisniewski et al., 1985; Antonarakis & Epstein, 2006; Wiseman et al., 2009 ). Other systemic manifestations including mental retardation, cardiovascular anomalies, craniofacial dysmorphology, malignant neoplasms such as acute myoblastic leukemia, and recurrent infections, are also seen in DS patients (Antonarakis & Epstein, 2006; Wiseman et al., 2009 ).
2.2. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A is a potential drug target of Down syndrome DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) is a serine/threonine kinase that is essential in the maintenance of normal development and function of the brain (Becker et al., 1998; Wiseman et al., 2009 ). The physiological importance of DYRK1A has recently been highlighted by its proposed relation with the pathogenesis of DS. This review briefly summarizes the proposed relationship of DYRK1A and DS, but the physiological function of DYRK1A and its pathogenic role in DS is extensively reviewed elsewhere (Becker & Sippl, 2011; Tejedor & Hammerle, 2011; Wegiel et al., 2011) .
Initially, DYRK1A attracted the interest of researchers when it was found within the 'Down Syndrome Critical Region (DSCR)' of human chromosome 21, the genomic region that was considered to explain the most of the DS symptoms at that time (Guimera et al., 1996; Shindoh et al., 1996; Song et al., 1996) . Although now it is revealed that the complex gene interactions that include genes outside the DSCR contribute to various DS phenotypes, DCSR genes are still considered to contribute to the neuropsychiatric manifestations (Olson et al., 2007; Korbel et al., 2009 ). Importantly, the extra copy of DYRK1A gene in DS indeed results in 1.5-fold increase of DYRK1A product both at mRNA and protein levels in their brain (Guimera et al., 1999; Dowjat et al., 2007; Wegiel et al., 2008; Vilardell et al., 2011) . It is proposed that this subtle increase of the enzymatic activity takes a broad consequence on the aberrant development of the brain.
Another observation that links DYRK1A to DS pathogenesis is its essential role on neurogenesis and neural differentiation. The molecular targets of DYRK1A make an ever increasing list that currently includes more than 20 substrates and a dozen of interactive proteins (Tejedor & Hammerle, 2011) . Through such phosphorylation events and protein interactions, DYRK1A functions in a remarkably broad aspect of cellular processes such as cell cycle regulation, cellular signaling, chromatin modulation and gene expression, regulation of alternative splicing, and membrane trafficking (Tejedor & Hammerle, 2011) . DYRK1A thus regulates the neurogenesis, neural differentiation, dendritogenesis, synapse function and cell death (Wegiel et al., 2011) . To exert the diversified roles throughout the life cycle of neurons, DYRK1A itself shows a regulated spatiotemporal expression and cellular localization that changes according to different stages of neural development by yet unknown mechanisms (Hammerle et al., 2003; Hammerle et al., 2008; Kida et al., 2011) . Considering its significant breadth of cellular functions, DYRK1A may function as a coordinator/balancer in developing neurons, and its imbalance may induce profound change in brain functions.
Lastly and most importantly, several studies using different lines of transgenic mice revealed that overexpression of Dyrk1A alone is sufficient to induce brain morphology alterations as well as neurological and motor disorder that resemble some of DS manifestations (Smith et al., 1997; Altafaj et al., 2001; Branchi et al., 2004; Martinez de Lagran et al., 2004; Ahn et al., 2006; Altafaj et al., 2008; Laguna et al., 2008; Ortiz-Abalia et al., 2008; Sebrie et al., 2008) . There are several genetically modified mouse lines that overexpress Dyrk1A; that are due to amplification of murine chromosome 16 (Ts65Dn, Ts1Cje, TsRhr, etc.) (Guimera et al., 1999; Dowjat et al., 2007; Roubertoux & Carlier, 2010; Yu et al., 2010) , human chromosome 21 (Tc1) (O'Doherty et al., 2005) , introduction of yeast artificial chromosome (152 F7) (Smith et al., 1997; Branchi et al., 2004) , bacterial artificial chromosome (DYRK1A BAC mouse) (Ahn et al., 2006) , and single gene overexpression (TgDyrk1A) (Altafaj et al., 2001; Martinez de Lagran et al., 2004; Altafaj et al., 2008; Ortiz-Abalia et al., 2008) . They commonly exhibit cognitive defects, such as learning and memory impairment, although the alteration of brain morphologies, and size are not always consistent between these animals, possibly reflecting the complex genetic interactions.
Misregulated alternative splicing in Down syndrome
Although DS is a typical "gene dosage" disease, DS also has an aspect of disease mediated by misregulated alternative splicing of multiple mRNAs. DYRK1A phosphorylates the splicing factors such as SRSF1/ASF, SRSF2/SC35, SRFS7/9G8 and SF3B1/SAP155 (de Graaf et al., 2006; Shi et al., 2008; Ding et al., in press; Qian et al., 2011) . SRSF1/ASF, SRSF2/SC35 and SRFS7/9G8 belong to the SR protein family of splicing factors that contain Ser/Arg rich domains. SR proteins bind to specific elements of pre-mRNA and enhance or suppress the inclusion of alternative exons. Their activities are regulated by phosphorylation of the RS domains and thus changes in activities of their upstream kinases may exert global effect on alternative splicing patterns (Long & Caceres, 2009; Shepard & Hertel, 2009 ). Toiber et al. reported that in fetal DS brains, phosphorylation levels of SR proteins were elevated, and in addition, gene expression levels of multiple splicing related proteins were altered. They examined the mRNAs of TRKB and AChE in fetal DS brains and found changes in alternative splicing patterns in a way that may contribute to the DS phenotype. Stable overexpression of Dyrk1A in mouse brain mimicked these findings if not completely (Toiber et al., 2010) .
Role of dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A in Down syndrome associated Alzheimer disease
Excessive activities of DYRK1A may accelerate AD pathogenesis because it results in the formation of neurotoxic NFT in AD brains through two mechanisms; by triggering the multiple phosphorylation of the tau protein, and by inducing aberrant alternative splicing of tau. In vitro experiments showed that DYRK1A phosphorylates the tau protein at Thr212, then the phosphorylated tau became prone to phosphorylation by GSK3β and other kinases at multiple sites, leading to its pathogenic aggregation and formation of NFT (Woods et al., 2001; Ryoo et al., 2007; . Studies of the AD patient brains revealed the increased expression of DYRK1A in both the brains and the specific neurons affected by tau aggregation (Ferrer et al., 2005; Kimura et al., 2007; Wegiel et al., 2008) . NFT formation is also enhanced by the imbalanced alternative splicing of its premRNA. Exon 10 inclusion/exclusion of tau is regulated by SR proteins SRSF1/ASF and SRSF2/SC35 that are substrates of DYRK1A (Shi et al., 2008; Qian et al., 2011) . SRSF1/ASF and SRSF2/SC35 bind to exonic splicing enhancers at exon 10 and promote its inclusion in mRNA thus generating the 4R-tau form. Phosphorylation of these SR proteins by DYRK1A releases these splicing factors from the splicing enhancers and results in formation of 3R-tau that lacks exon 10 (Shi et al., 2008; Qian et al., 2011) . In a normal state, nearly equal amount of 3R-tau and 4R-tau, forms of tau, is expressed in adult brain. If this balance is lost and turns to 3R-tau predominance, tauopathy is induced . Other reports show the direct and indirect association of excess DYRK1A activity and enhanced toxicity of amyloid precursor protein that also plays an essential role in AD pathogenesis (Ryoo et al., 2008) .
INDY, a novel inhibitor of dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
In order to invent the potential DS and AD drugs, we searched for specific inhibitors of DYRK1A, and found that benzothiazole derivatives have a potent inhibitory effect on the kinase activity. Among them, (1Z)-1-(3-ethyl-5-hydroxy-2(3H)-benzothiazoylidene)-2-propanone, which we referred to as INDY (inhibitor of Dyrk) (Fig. 1) , was the most potent compound with an IC50 of 0.24 μM (Ogawa et al., 2010) . INDY also inhibited DYRK1B, the closest DYRK kinase family member to DYRK1A, with an IC50 of 0.23 μM. Otherwise, INDY had high kinase selectivity; in an in vitro assay screening using a panel of 66 protein kinases, INDY (10 μM) showed >90% inhibition on DYRK2, DYRK3 and four other kinases, namely CLK1, CLK4, CSNK1D and PIM1. The X-ray crystallography of the DYRK1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme (Ogawa et al., 2010) .
Harmine, a plant alkaloid, is one of the most potent DYRK1A inhibitor reported to date (Bain et al., 2007; Gockler et al., 2009 ). Inhibition of DYRK1A by INDY was comparable to that by harmine, which showed a higher IC50 (0.35 μM) in our assay compared to the past reports, presumably due to the different experimental conditions. Interestingly, harmine also inhibited Clks at a level comparable to the inhibition by INDY, implying a similar structural mechanism of inhibitory action. Unfortunately, utility of harmine in the field of brain research is limited by the fact that it also inhibits monoamine oxidase (MAO) A at a considerably lower dose (IC50 = 5 nM) than required for inhibiting DYRK and Clk family kinases (Kim et al., 1997) . INDY, however, was substantially free of MAOA inhibitory activity. Their similar kinase inhibitory potential and the contrasting difference in MAOA inhibitory potential were explained by comparing the X-ray crystallographies. INDY and harmine employed markedly similar manner to bind the DYRK1A ATP pocket; a result that is consistent with the observed kinase selectivity of the two compounds. In case of MAOA, INDY could reproduce many hydrophobic interactions between harmine and MAOA, according to the hypothetical INDY/MAOA complex structure deduced from reported harmine/MAOA model. It was suggested, however, that INDY may interfere with Asn181 or Phe208 of MAOA, as well as disturb a network of water-mediated hydrogen bonds of MAOA, thus preventing the complex formation (Ogawa et al., 2010) .
In cultured cells, INDY effectively reversed the aberrant tau phosphorylation and rescued the skewed cellular signaling events induced by DYRK1A overexpression. To further validate the utility of the DYRK1A inhibitor, we developed a novel in vivo assay. For this purpose we utilized Xenopus laevis embryo as an ideal platform to observe the general effects of Dyrk1A overexpression, because it allows an in vivo assay at a level of whole vertebrate development while also allowing a relatively high throughput. When Xenopus Dyrk1A mRNA was injected into two animal dorsal blastomeres of 8-cell embryos, deformity was observed in the eye and the head of the tadpoles that was accompanied by dorsal deformation in some cases. Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Xenopus Dyrk1A overexpression, resulting in normally developed embryos (Ogawa et al., 2010) . These experiments demonstrate the utility of proINDY in vivo, indicating the possibility that INDY and proINDY have therapeutic utility on neuropsychiatric symptoms of DS and early onset AD associated with DS. Further studies using DS and AD model mice are warranted to prove their clinical benefits of these DYRK1A inhibitors.
3. Chemical treatment of muscular dystrophies 3.1. TG003, as a mutated-exon skipping enhancer DMD is the most common inherited muscle disease and is caused by a mutation in the dystrophin gene, the largest in the human genome, on the X chromosome 1 (Koenig et al., 1988) . Because of progressive muscle wasting, DMD patients usually succumb to cardiac or respiratory failure in their twenties. Becker muscular dystrophy (BMD) is a milder allelic variant of DMD, usually affecting adult males. Nonsense mutations or deletions causing frame shifts in the dystrophin mRNA, both of which create premature termination codons (PTCs), usually result in a severe DMD phenotype, because of a lack of the dystrophin protein . Recently, we met a dystrophinopathy patient who has a previously unreported point mutation in exon 31 of the dystrophin gene that was not seen in more than 400 other dystrophinopathy patients we studied. Although the mutation generates a stop codon, a small amount of internally deleted, but functional, dystrophin protein was produced in the patient cells. An analysis of the mRNA revealed that the mutation promotes exon skipping and restores the open reading frame of dystrophin (Nishida et al., 2011) . We found that the c.4303G>T mutation in this patient disrupted an exonic splicing enhancer that promotes exon 31 inclusion. Interestingly, the mutation simultaneously produced an exonic splicing silencer that binds to hnRNP A1 and promotes skipping of the same exon. Skipping of 111-bp-long exon 31 results in an in-flame internal deletion that leads to the production of an internally deleted but functional dystrophin. We hypothesized that a customized RNA-targeted therapy specific for this patient would become possible by promoting the skipping of the exon 31 (Fig. 2) . Therefore we searched for small chemicals that enhance exon skipping, and found that TG003, which is a compound we developed as a specific inhibitor Clk1 and Clk4, promoted the skipping of exon 31 in the endogenous dystrophin gene in a dose-dependent manner and increased production of the dystrophin protein in the patient's cells (Fig. 1) (Muraki et al., 2004; Nishida et al., 2011) . Since Clk1 and Clk4 kinase activity regulates alternative splicing events by phosphorylating some SR proteins, TG003 may produce an unphosphorylated form of a SR protein that functions as an inhibitor of exon 31 inclusion and enhances exon skipping corporately with hnRNPA1. TG003 did not affect splicing of wild type exon 31 or other normal exons of the dystrophin gene.
Though more preclinical studies with animal models are needed, TG003 is the first chemical compound verified to improve dystrophin production in in vitro patient-derived myotubes.
Stop codon read through drugs
A part of DMDs are caused by premature stop codons in the dystrophin gene that arise from the gene mutation (Muntoni et al., 2003) . Some aminoglycoside antibiotic such as gentamicin allows the ribosome machinery to skip or "read through" the stop codons (Wagner et al., 2001) (Fig. 3) . Treatment of the mdx mouse, a model mouse of nonsense mutation of DMD, with gentamicin increased the expression of dystrophin by up to 20%, and improved the muscle manifestations (Wagner et al., 2001) . Since prolonged systemic administration of gentamicin has the adverse effect of nephrotoxicity and ototoxicity, alternative therapeutic chemical compounds have been developed. PTC124, a small chemical developed by PTC Therapeutics, is an orally administrated drug that targets the 60S ribosomal subunit and induces the selective read through of the nonsense mutations. Experiments with mdx mice demonstrated somewhat better ability of PTC124 in recovery of their muscle phenotypes compared to gentamicin (Welch et al., 2007) . Phase I studies for PTC124 showed that this drug is well tolerated, and data from a Phase IIb study suggested that PTC124 has clinical benefit in nonsense mutation-DMD patient when it is used in relatively low doses but not in high doses (PTC Therapeutics website, http://www.ptcbio.com/). PTC124 is now in Phase III trials in cystic fibrosis patients who have disease-causing premature stop codons in CFTR gene (ClinicalTrials.gov identifier: NCT01140451).
RNA binding compounds
The other strategy to develop "RNA-targeting" drugs is to find compounds that bind to RNA itself. Myotonic dystrophy (MD) is an inherited neuromuscular degenerative disease, characterized by muscular dystrophy and other systemic manifestation including myotonia, impaired glucose tolerance, cataracts, and cardiac abnormalities (La Spada et al., 1994) . Two types of MD, namely MD1 and MD2, have been well characterized (Lee & Cooper, 2009) . MD1, that is estimated to affect~1 in 8500 individuals, is caused by the mutation of the DMPK gene. In MD1 patients, 3′ UTR of the DMPK gene contains aberrantly expanded trinucleotide repeats of CTG. In case of MD2, tetranucleotide repeats of CCTG are expanded in the first intron of the CNBP gene (Lee & Cooper, 2009) . When transcribed into pre-mRNAs, these nucleotide repeats inflict the pathogenic potentials through the RNA gain-of-function mechanism (Fig. 4) . In case of MD1, the expanded CUG repeat captures the splicing factor muscleblind-like protein 1 (MBNL1) and results in relative loss of function of the protein, while another splicing factor, CUG triplet repeat RNA binding protein 1 (CUGBP1), is upregulated due to altered cellular signaling events involving protein kinase C (Philips et al., 1998; Miller et al., 2000; Kuyumcu-Martinez et al., 2007; Lee & Cooper, 2009; Wang et al., 2009) . Since MBNL1 and CUGBP1 are key splicing factors that regulate the global alternative splicing patterns, subsequent dysregulation of alternative splicing results in systemic dysfunctions including the muscular dystrophy (Mankodi et al., 2000) . In a search for small chemical inhibitors that counter the RNA gain-of-function effect in DM1, Warf MB et al. found that pentamidine, an antibiotic used in Pneumocystis pneumonia, binds to the CUG repeats and inhibits the binding of MBNL1 in vitro (Fig. 4) . Using a mouse model that expresses expanded CUG repeats, they demonstrated that pentamidine rescues missplicing events in the muscle at least partially, although full rescue was not achieved due to the toxicity of the drug that appeared in high dose treatments (Warf et al., 2009 ). Development of improved compounds with higher specificity to CUG repeats is awaited. 
Chemical treatment of Denys Drash Syndrome

SRPIN340, as another alternative splicing-modifying chemical drug
SRPKs represent another kinase family that phosphorylates SR proteins and regulates alternative splicing patterns (Gui et al., 1994; Kuroyanagi et al., 1998) . In search of novel chemical splicing modifying drugs, we performed an extensive screening of 100,000 chemical compounds, and found a synthetic compound as specific inhibitors of SR protein kinases (SRPKs) (Fukuhara et al., 2006) . The compound, which we named SRPIN340, had potential clinical utilities in treatments of viral infection and anti-angiogenesis therapies against retinal neovasculization and certain tumors (Fukuhara et al., 2006; Karakama et al., 2010; Nowak et al., 2010; Amin et al., 2011) (Fig. 1) .
Vascular Endothelial Growth Factor (VEGF) is a key regulatory component in physiological and pathological angiogenesis. Two types VEGF isoforms, the pro-angiogenic isoforms and the anti-angiogenic isoforms are generated by splice site choice in the exon 8. Proximal splice site selection in exon 8 generates pro-angiogenic isoforms such as VEGF165, and distal splice site selection results in anti-angiogenic isoforms such as VEGF165b (Qiu et al., 2009) . Epithelial cells treated with IGF-1 increased proximal splice site selection and produced more angiogenic isoforms. On the contrary, SRPK1/2 inhibition promoted distal splice site selection and produced more anti-angiogenic isoforms (Fig. 5) . Injection of SRPIN340 reduced angiogenesis in a model of retinal neovascularization . DDS patients who have a genetic mutation in the Wilm's tumor suppressor gene WT1 have increased risk of Wilm's tumor, a highly vascularized tumor with high VEGF levels. A recent study demonstrated that SRPIN340 functions as anti-angiogenic drugs for these tumors by switching the splicing pattern of VEGF toward the production of anti-angiogenic VEGF165b and other anti-angiogenic isoforms (Amin et al., 2011) .
Conclusion
For many congenital genetic diseases, no treatments are available besides common palliative therapies. We sought for novel cure for two such congenital diseases, DS and DMD, and identified INDY and TG003 as possible chemical therapeutic agents. In addition, SRPIN340 may be applicable for anti-angiogenic therapy such as those against Wilm's tumors of DDS patients.
Current sophisticated sequencing techniques allow us to sequence the human genomes and transcriptomes in a reasonably affordable cost and time (Ku et al., 2011) . It gives us the hope that genetic defects of a given patient may be pinpointed to a single base in the near future and that we then may be able to understand the precise molecular basis of the disease on the level of the RNA life cycle. In addition, considering that many well-designed, large chemical libraries being now increasingly accessible, more chemical tools are expected to turn out in the near future that allows us fine manipulations of RNA processing (Thomas et al., 2009; Roy et al., 2010) . Combined with the advancing knowledge on the mechanisms how the splicing codes are deciphered and how to manipulate them, RNA targeted therapies would be designed according to the gene alteration and the following mRNA defects unique to individual patients as the researches will advance in this exciting field.
While it is not yet possible to restore the disease-causing genetic aberrations in the level of DNA, new drugs may be discovered that mitigate the disease symptoms by chemically manipulating the amounts and patterns of disease-causing mRNAs. For future development of small chemical compound drugs for many genetic diseases, more research must be aimed at the molecular mechanisms that can influence the mRNA processing and functions, as well as knowledge of key molecules that are central to the pathogenesis of each disease. VEGF gene produces pro-and antiangiogenic alternative splicing isoforms by the selective usage of the splicing site in the last exon. Activation of SRPK1/2 results in an increase in the pro-angiogenic isoforms (e.g. VEGF165). Inhibition of SRPK1/2 by SRPIN340 results in increased production of anti-angiogenic isoforms (e.g. VEGF165b).
